Plain-English translation of NCT05299840 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the Oncogramme® device, a new personalized medicine tool that analyzes your individual tumor cells to see which chemotherapy drugs would work best for you. Right now, doctors choose chemotherapy based on general guidelines that work for most patients, but this test aims to personalize that choice by testing your specific cancer cells against available treatments to find the one most likely to help you.
Advanced colorectal cancer is serious, and current treatment choices are based on what works for large patient groups rather than what works for each individual. This test exists because it may help doctors select a chemotherapy regimen that is more effective for your specific tumor and reduces unnecessary side effects.
You likely qualify if…
You likely don't qualify if…
If you join this trial, your tumor tissue will be sent to the lab for the Oncogramme® test, which analyzes how your cancer cells respond to different chemotherapy drugs. You will then be randomly assigned to one of two groups: one group where your doctor uses the test results to help choose your treatment, and another group where your doctor chooses treatment using standard guidelines. Either way, you will receive chemotherapy and be monitored during your visits to see how well it works, measure any side effects, and track your quality of life over time.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
France